Aspergillus-specific IgM/IgG antibody serostatus of patients hospitalized with moderate-critical COVID-19 in Uganda

Felix Bongomin1, Richard Kwizera2, Emmanuel Mande2, Sharley Melissa Aloyo3, Beatrice Achan4, Martha Namusoby4, Senai Goitom Sereke6, Charles Batte7, Sarah Kiguli8, Joseph Baruch Baluku5,9, Moses L Joloba3, Bruce J Kirenga7

1. Department of Medical Microbiology and Immunology, Gulu University Medical School, Gulu Uganda
2. Translational research laboratory, Department of Research, Infectious Diseases Institute, College of Health Sciences, Makerere University, PO Box 22418, Kampala, Uganda.
3. Department of Immunology and Molecular Biology, Makerere University College of Health Sciences, Kampala, Uganda.
4. Department of Medical Microbiology, College of Health Sciences, Makerere University, Kampala, Uganda.
5. Department of Internal Medicine, Mulago National Referral Hospital, Kampala, Uganda
6. Department of Radiology and Radiotherapy, College of Health Sciences, Makerere University, Kampala, Uganda.
7. Makerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
8. Department of Pediatrics and Child Health, College of Health Sciences, Makerere University, Kampala, Uganda.
9. Directorate of Programs, Mildmay Uganda, Wakiso, Uganda.

Abstract

Invasive pulmonary aspergillosis is known to complicate the coronavirus diseases-2019 (COVID-19), especially those with critical illness. We investigated the baseline anti-Aspergillus antibody serostatus of patients with moderate-critical COVID-19 hospitalized at 3 COVID-19 Treatment Units in Uganda. All 46 tested patients, mean age 30, and 11% with underlying respiratory disease had a negative serum anti-Aspergillus IgM/IgG antibody immunochromatographic test on day 3 (mean) of symptom onset (range 1-26), but follow up specimens to assess seroconversion were not available.

Keywords: Invasive pulmonary aspergillosis, COVID-19, critical illness, Uganda.

DOI: https://dx.doi.org/10.4314/ahs.v22i3.54

Cite as: Bongomin F, Kwizera R, Mande E, Aloyo SM, Achan B, Namusoby M, et al. Aspergillus-specific IgM/IgG antibody serostatus of patients hospitalized with moderate-critical COVID-19 in Uganda. Afri Health Sci. 2022;22(3): 506-511. https://dx.doi.org/10.4314/ahs.v22i3.54

Background

The coronavirus disease-2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has affected millions of individuals since December 2019, resulting in significant morbidity and mortality globally. As of 30th September, 2021, over 234 million had contracted the disease, resulting to over 4.8 million deaths, worldwide. Experience from previous influenza pandemics have shown that microbial co-infection increases the risk of disease severity in humans infected with viral infections. A number of studies have documented SARS-CoV-2 co-infection with other pathogens. Moreover, microbial co-infection occurs very early in patients with COVID-19. Aspergillus species are ubiquitous environmental molds that cause a spectrum of clinical pulmonary syndromes ranging from allergic, invasive and chronic disease with varying severity and clinical outcomes depending on the immune status of the host and the virulence of the etiologic Aspergillus species. Recently, fungal pathogens notably Candida, Histoplasma, Cryptococcus and Aspergillus species co-infections have been reported in patients with COVID-19 associated with a particularly poor outcomes.

COVID-19 associated pulmonary aspergillosis (CAPA), is frequently observed in patients with moderate to severe COVID-19 disease, especially those on immunosuppressive therapy, underlying lung disease and those requiring invasive mechanical ventilation or extracorporeal membranous oxygenation. In published case series, CAPA has been reported to have a very high mortality rate in...
excess of 50%\textsuperscript{7–9}. Therefore, early recognition and institution of appropriate antifungal agents is key to improve outcomes\textsuperscript{8}.

As of 30\textsuperscript{th} September, 2021, Uganda has recorded over 123,500 cases of COVID-19 with over 3,150 of these patients dying from the disease\textsuperscript{1}. In the first wave of the pandemic, much as a vast majority of Ugandan patients diagnosed with COVID-19 were asymptomatic or had a mild disease (10), about 4\% of the patients had moderate to severe disease. However, in the second wave, close to 80\% of hospitalized patients had moderate-severe COVID-19\textsuperscript{11}. These patients are at increased risk of CAPA. This study therefore, aimed at determining anti-Aspergillus specific IgG/IgM serostatus in patients with moderate and severe COVID – 19 in Uganda to guide future studies and clinical care of these patients who are at risk of CAPA.

Patients and Methods
In January 2021, we conducted a laboratory-based, retrospective observational study on blood samples of patients hospitalized and managed for COVID-19 at three COVID-19 treatment units (CTUs) in Uganda, namely Mulago National Referral Hospital (MNRH), Entebbe Regional Referral Hospital (ERRH) and Arua Regional Referral Hospital (ARRH).

Biobanked serum samples of patients hospitalized with moderate, severe, critical COVID-19 defined by the need for oxygenation or mechanical ventilation were randomly selected. Demographic characteristics, co-morbidities and clinical outcomes of the patients were retrieved from the Integrated Biorepository of H3Africa Uganda (IBRH3AU) electronic database. IBRH3AU is situated in the Department of Immunology and Molecular Biology, School of Biomedical Sciences, Makerere University College of Health Sciences, Kampala, Uganda. The biorepository has in storage well annotated different sample types from over 500 COVID-19 patients and out of these, 46 serum samples of the eligible patients were randomly selected.

Thawed serum samples of the eligible patients were examined using the commercially available anti-Aspergillus IgM/IgG antibody immunochromatographic technology (ICT) lateral flow assay, which has excellent sensitivity (88.9–91.6\%) and specificity (96.3–98\%) (LDBio Diagnostics, Lyon, France)\textsuperscript{12–15}. STATA version 16 was used to produce descriptive statistics.

Patient Consent Statement
This study was approved by the Makerere University School of Biomedical Sciences Research and Ethics Committee Approval number; MHREC 1868. Patients records were registered using anonymous alpha-numeric codes and principles outlined in the Declaration of Helsinki were observed.

Results
We tested 46 serum samples from 46 unique individuals (Male n=38, Female n=8). The median age of the participants was 34 (range: 14-54) years. Forty (87\%) patients had co-morbidities, mainly diabetes and cardiovascular diseases. The median duration of illness prior to hospitalization was 3 days (range: 1-26 days). Shortness of breath was the most common symptom reported by 42 (91.3\%) participants followed by cough (37\%), headache (32.6\%) and fever (26.1\%). Table 1

Sixteen (34.8\%) patients were hospitalized in the intensive care unit, with 8 (50\%) of them requiring invasive mechanical ventilation. Twenty-seven (58.7\%) patients received azithromycin, 12 (26.1\%) hydroxychloroquine and 16 (34.8\%) dexamethasone in addition to supportive care. Table 1
Table 1: Characteristics of patients evaluated for Aspergillus IgG/IgM serostatus

| Characteristics                  | Frequency/median | Percent/range |
|----------------------------------|-----------------|---------------|
| **Treatment center**             |                 |               |
| Entebbe Regional Referral Hospital | 20              | 43.5          |
| Mulago National Referral Hospital  | 17              | 37.5          |
| Arua Regional Referral Hospital  | 9               | 19.6          |
| **Sex**                          |                 |               |
| Male                             | 38              | 82.6          |
| Female                           | 8               | 17.4          |
| **Age, years**                   | 34              | 14-54         |
| **Occupation**                   |                 |               |
| Truck drivers                    | 20              | 43.5          |
| Business                         | 12              | 26.1          |
| Professionals                    | 12              | 26.1          |
| Students                         | 2               | 4.3           |
| **Clinical symptoms**            |                 |               |
| Fever                            | 12              | 26.1          |
| Cough                            | 17              | 37.0          |
| Hemoptysis                       | 1               | 2.2           |
| Rhinorrhea                       | 12              | 26.1          |
| Chest pain                       | 4               | 8.7           |
| Shortness of breath              | 42              | 91.3          |
| Headache                         | 15              | 32.6          |
| **Comorbidities**                |                 |               |
| Diabetes mellitus alone          | 12              | 30.0          |
| Hypertension alone               | 8               | 20.0          |
| HIV alone                        | 3               | 7.5           |
| Diabetes and hypertension        | 10              | 25            |
| Diabetes + HIV                   | 2               | 5             |
| Asthma                           | 3               | 7.5           |
| Chronic obstructive pulmonary disease alone | 2            | 5             |
| **Treatment**                    |                 |               |
| Azithromycin                     | 27              | 58.7          |
| Hydroxychloroquine               | 12              | 26.1          |
| Dexamethasone                    | 16              | 34.8          |
| **Level of care**                |                 |               |
| Intensive care unit – invasive mechanical ventilation | 8 | 17.4 |
| Intensive care unit – non-invasive ventilation | 8 | 17.4 |
| High dependency unit - Oxygenation | 30          | 65.2          |

Serum anti-Aspergillus IgM/IgG lateral flow assay tests were negative for all the patients.

**Discussion**
There is increasing evidence on the increased frequency and poor outcomes of invasive pulmonary aspergillosis in patients with severe/critical COVID-19. In this report, we investigated baseline anti-Aspergillus antibody serostatus of patients hospitalized with moderate-critical COVID-19 in Uganda. All the participants tested negative for serum anti-Aspergillus IgM/IgG antibody. These findings can be interpreted in 2 ways. Firstly, CAPA may be an uncommon occurrence in our settings. This is supported by a large retrospective study reporting a relatively lower incidence of invasive aspergillosis in patients with COVID-19 acute respiratory distress syndrome (ARDS) compared with non-COVID-19 ARDS. Secondly, serum anti-Aspergillus IgM/IgG lateral flow assay may be an unreliable screening tool for CAPA. This is consistent with findings from recent studies showing that con-
ventional diagnostics for invasive pulmonary aspergillosis may miss most cases of CAPA. However, this assay has been validated for the diagnosis of invasive pulmonary aspergillosis and sub-acute invasive pulmonary aspergillosis. Also, the median duration of hospitalization for the participants was short, as CAPA has been reported to occur in around the 8th to 10th day. A negative anti-Aspergillus IgM/IgG also rule out any possibility of underlying chronic pulmonary or allergic bronchopulmonary aspergillosis among the participants.

The knowledge of the risk factors and burden of CAPA remains limited. There is no known established risk factor for the development of CAPA and patients with CAPA in most cases do not have the classic risk factors for invasive aspergillosis. A study from France did not find any difference between patients with and without invasive pulmonary aspergillosis regarding age, gender, medical history and severity on admission and during hospitalization.

In this particular study, high doses of corticosteroids and azithromycin usage were associated with increased frequency of occurrence of invasive aspergillosis. In published literature, the incidence of CAPA has been reported to range anywhere between 20 and 35%. However, prolonged corticosteroid therapy, ICU admission and COVID-19 itself may be possible risk factor for this emerging disease. Based on small case series, mortality rates associated with CAPA is as high as 70%.

Thus, the diagnostic work up for CAPA remains a work in progress. Among ICU patients, CAPA patients had a lower positive culture or polymerase chain reaction (PCR) or galactomannan test on bronchoalveolar lavage fluid compared to influenza patients. A panel of experts on CAPA suggests that the European Organization for Research and Treatment of Cancer and the Mycosis Study Group Education and Research Consortium definitions for invasive fungal disease may not be suitable for the diagnosis of CAPA or its related syndrome - influenza-associated pulmonary aspergillosis. This panel proposed CAPA to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. A proven diagnosis of CAPA requires at least one of the following: histopathological or direct microscopic detection of fungal hyphae, showing invasive growth with associated tissue damage; or Aspergillus recovered by culture or microscopy or histology or PCR obtained by a sterile aspiration or biopsy from a pulmonary site, showing an infectious disease process.

To-date, no randomized clinical trial has evaluated any antifungal regimen for the treatment of CAPA. Current treatment approach is based on the basic principles of antifungal therapy extrapolated from experience and evidence of treating invasive aspergillosis in other population. As such, voriconazole or isavuconazole have been recommended as first-line treatment for possible, probable, and proven CAPA. Cases of azole-resistant Aspergillus fumigatus causing CAPA has been reported. This poses therapeutic dilemma. Alternative antifungal agents such as amphotericin B and the echinocandins may as well have a role in the management of CAPA. However, evidence on the use of these agents remains scarce.

**Limitation**

The reader should consider the following limitation while interpreting the finding of our study. Importantly, the diagnosis of CAPA requires a combination of factors including mycological, host, clinical and histopathological factors. Therefore, evaluation of a patient based on a single modality is best considered a screening tool. Also, our sample size is very small and we may have missed some cases in the larger sample pool.

In summary, among patients hospitalized with severe/critical COVID-19 in Uganda, we failed to find any evidence of current or prior immune response to Aspergillus infection. This finding potentially provides a useful clinical information on the rarity of Aspergillus infection among COVID-19 patients in Uganda. However, further research utilizing better diagnostic modalities is required.

**Funding**

The study did not receive any specific funding

**Conflict of interest**

The authors declare they do not have any conflict of interests.

**Availability of data and material**

The underlying data can be accessed through the corresponding author on reasonable request.

**Code availability**

Not applicable
Acknowledgement

We acknowledge the contribution of The Integrated Biorepository of H3Africa Uganda (IBRH3AU) towards this research work. We thank Professor David W. Denning of the University of Manchester, UK for generously donating the Aspergillus IgG/IgM testing kits.

Conflict of Interests

None.

References

1. Woldometer. COVID-19 Coronavirus Pandemic [Internet]. 2021. Available from: https://www.worldometers.info/coronavirus/

2. Joseph C, Togawa Y, Shindo N. Bacterial and viral infections associated with influenza. Influenza Other Respi Viruses [Internet]. 2013 Sep;7:105–13. Available from: http://doi.wiley.com/10.1111/irv.12089

3. Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res [Internet]. 2020 Aug;285:198005. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0168170220303531

4. Latgé JP, Chamilos G. Aspergillus fumigatus and aspergillosis in 2019. Clin Microbiol Rev [Internet]. 2020 Nov 13;33(1):1–75. Available from: https://cmr.asm.org/content/33/1/e00140-18

5. Song G, Liang G, Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia [Internet]. 2020 Aug;185(4):599–606. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32737747

6. Cafardi J, Haas D, Lamarre T, Feinberg J. Opportunistic Fungal Infection Associated with COVID-19. Open Forum Infect Dis [Internet]. 2021 Jan 18; Available from: https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab016/602577

7. Dupont D, Menotti J, Turc J, Miossec C, Wallet F, Richard J-C, et al. Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19). Med Mycol [Internet]. 2020 Sep 10; Available from: https://academic.oup.com/mmy/advance-article/doi/10.1093/mmy/myaa078/5903915

8. White PL, Dhillon R, Cordey A, Hughes H, Faggian F, Soni S, et al. A National Strategy to Diagnose Coronavirus Disease 2019–Associated Invasive Fungal Disease in the Intensive Care Unit. Clin Infect Dis [Internet]. 2020 Aug 29; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1298/5899192

9. Machado M, Valerio M, Álvarez-Uría A, Olmedo M, Veintimilla C, Padilla B, et al. Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity. Mycoses [Internet]. 2020 Nov 29;myc.13213. Available from: https://onlinelibrary.wiley.com/doi/10.1111/myc.13213

10. Kirenga B, Muttamba W, Kayongo A, Nserekoko C, Siddharthan T, Lusiba J, et al. Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda. BMJ Open Respir Res [Internet]. 2020 Sep 7;7(1):e000646. Available from: https://bmjopenrespres.bmj.com/lookup/doi/10.1136/bmjresp-2020-000646

11. Uganda Virus Research Institute. Kampala registers Indian Covid-19 variant [Internet]. UVRI. 2021 [cited 2021 Jul 12]. Available from: https://www.uvri.go.ug/news/kampala-registers-indian-covid-19-variant

12. Piarroux RP, Romain T, Martin Vainqueur D, Vitte J, Lachaud L, et al. Multicenter evaluation of a novel immunochromatographic test for anti-aspergillus IgG detection. Front Cell Infect Microbiol. 2019;9(JAN):1–7.

13. Stucky Hunter E, Richardson MD, Denning DW. Evaluation of LDBio Aspergillus ICT Lateral Flow Assay for IgG and IgM Antibody Detection in Chronic Pulmonary Aspergillosis. J Clin Microbiol [Internet]. 2019 Sep;57(9). Available from: http://www.ncbi.nlm.nih.gov/pubmed/31217272

14. Hunter ES, Page ID, Richardson MD, Denning DW. Evaluation of the LDBio Aspergillus ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis. Kniemeyer O, editor. PLoS One [Internet]. 2020 Sep 25;15(9):e0238855. Available from: https://dx.plos.org/10.1371/journal.pone.0238855

15. Rozaliyani A, Rosianawati H, Handayani D, Agustin H, Zaini J, Syam R, et al. Chronic Pulmonary Aspergillosis in Post Tuberculosis Patients in Indonesia and the Role of LDBio Aspergillus ICT lateral flow assay for serodiagnosis of allergic bronchopulmonary aspergillosis. Kniemeyer O, editor. PLoS One [Internet]. 2020 Sep 25;15(9):e0238855. Available from: https://dx.plos.org/10.1371/journal.pone.0238855
17. Yusuf E, Vonk A, van den Akker JPC, Bode L, Sips GJ, Rijnders BJA, et al. Frequency of Positive Aspergillus Tests in COVID-19 Patients in Comparison to Other Patients with Pulmonary Infections Admitted to the ICU. J Clin Microbiol [Internet]. 2020 Dec 4; Available from: http://jcm.asm.org/lookup/doi/10.1128/JCM.02278-20

18. Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis [Internet]. 2020 Dec; Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309920308471

19. Lai C-C, Yu W-L. COVID-19 associated with pulmonary aspergillosis: A literature review. J Microbiol Immunol Infect [Internet]. 2020 Sep; Available from: https://linkinghub.elsevier.com/retrieve/pii/S1684118220302383

20. Dellière S, Dudoignon E, Fodil S, Voicu S, Collet M, Oillle P-A, et al. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort. Clin Microbiol Infect [Internet]. 2020 Dec; Available from: https://linkinghub.elsevier.com/retrieve/pii/S1198743X20307564

21. de Pauw B, Thomas J, Walsha, Donnelly JP, Stevens D a., Edwards JE, Calandra T, et al. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive. Clin Infect Dis. 2008;46(12):1813–21.

22. Meijer EFJ, Dofferhoff ASM, Hoiting O, Buil JB, Meis JF. Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report. J Fungi [Internet]. 2020 Jun 6;6(2):79. Available from: https://www.mdpi.com/2309-608X/6/2/79

23. Jin J, Wu D, Liu Y, Pan S, Yan JL, Aram JA, et al. Utility of CT assessment in hematology patients with invasive aspergillosis: A post-hoc analysis of phase 3 data. BMC Infect Dis. 2019;19(1):1–9.